Deals
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
“The good performance we saw in the third quarter has continued to further improve.
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.
David Roth, Chief Financial Officer of 4basebio AG, comments: “4basebio can now successfully acquire the desired number of shares in full.
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.
Funding to support GMP adenovirus manufacture for a first-in-human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
Founded by UKI2S with co-investment from LifeArc & Parkwalk to advance a diabetic macular edema gene therapy and other pipeline products
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.